Montjovent Marc-Olivier, Burri Nathalie, Mark Silke, Federici Ermanno, Scaletta Corinne, Zambelli Pierre-Yves, Hohlfeld Patrick, Leyvraz Pierre-François, Applegate Lee L, Pioletti Dominique P
Bone Bioengineering Group, Orthopedic Research Center, Swiss Federal Institute of Technology Lausanne, Switzerland.
Bone. 2004 Dec;35(6):1323-33. doi: 10.1016/j.bone.2004.07.001.
We envision the use of human fetal bone cells for engineered regeneration of adult skeletal tissue. A description of their cellular function is then necessary. To our knowledge, there is no description of human primary fetal bone cells treated with differentiation factors. The characterization of fetal bone cells is particularly important as the pattern of secreted proteins from osteoblasts has been shown to change during aging. In the first part of this work, human primary fetal bone cells were compared to adult bone cells and mesenchymal stem cells for their ability to proliferate and to differentiate into osteoblasts in vitro. Cell proliferation, gene expression of bone markers, alkaline phosphatase (ALP) activity, and mineralization were analyzed during a time-course study. In the second part of this paper, bone fetal cells behavior exposed to osteogenic factors is further detailed. The doubling time of fetal bone cells was comparable to mesenchymal stem cells but significantly shorter than for adult bone cells. Gene expression of cbfa-1, ALP, alpha1 chain of type I collagen, and osteocalcin were upregulated in fetal bone cells after 12 days of treatment, with higher inductions than for adult and mesenchymal stem cells. The increase of ALP enzymatic activity was stronger for fetal than for adult bone cells reaching a maximum at day 10, but lower than for mesenchymal stem cells. Importantly, the mineralization process of bone fetal cells started earlier than adult bone and mesenchymal stem cells. Proliferation of fetal and adult bone cells was increased by dexamethasone, whereas 1alpha,25-dihydroxyvitamin D3 did not show any proliferative effect. Mineralization studies clearly demonstrated the presence of calcium deposits in the extracellular matrix of fetal bone cells. Nodule formation and calcification were strongly increased by the differentiation treatment, especially by dexamethasone. This study shows for the first time that human primary fetal bone cells could be of great interest for bone research, due to their fast growth rate and their ability to differentiate into mature osteoblasts. They represent an interesting and promising potential for therapeutic use in bone tissue engineering.
我们设想利用人胎儿骨细胞进行成人骨骼组织的工程化再生。因此有必要对其细胞功能进行描述。据我们所知,尚无关于用分化因子处理的人原代胎儿骨细胞的描述。由于成骨细胞分泌蛋白的模式已显示在衰老过程中会发生变化,因此胎儿骨细胞的特性尤为重要。在这项工作的第一部分,将人原代胎儿骨细胞与成人骨细胞和间充质干细胞在体外增殖和分化为成骨细胞的能力进行了比较。在一项时间进程研究中分析了细胞增殖、骨标志物的基因表达、碱性磷酸酶(ALP)活性和矿化情况。在本文的第二部分,进一步详细阐述了暴露于成骨因子的胎儿骨细胞的行为。胎儿骨细胞的倍增时间与间充质干细胞相当,但明显短于成人骨细胞。处理12天后,胎儿骨细胞中cbfa-1、ALP、I型胶原α1链和骨钙素的基因表达上调,诱导程度高于成人骨细胞和间充质干细胞。胎儿骨细胞中ALP酶活性的增加比成人骨细胞更强,在第10天达到最大值,但低于间充质干细胞。重要的是,胎儿骨细胞的矿化过程比成人骨细胞和间充质干细胞开始得更早。地塞米松可增加胎儿和成人骨细胞的增殖,而1α,25-二羟基维生素D3未显示任何增殖作用。矿化研究清楚地证明了胎儿骨细胞的细胞外基质中存在钙沉积。分化处理,尤其是地塞米松,可显著增加结节形成和钙化。这项研究首次表明,人原代胎儿骨细胞因其快速的生长速度和分化为成熟成骨细胞的能力,可能对骨研究具有重要意义。它们在骨组织工程的治疗应用中具有有趣且有前景的潜力。